[BONUS] "Jen Horonjeff is Noncompliant" The Clinical Trial Quid-Pro-Quo

Written By Kenny Kane

[audio mp3="https://pdcn.co/e/rss.art19.com/episodes/f96d8c19-9515-49b9-b87c-29d630a1879c.mp3?rss_browser=BAhJIgljdXJsBjoGRVQ%3D--435795d5c850773aaa4739d968bd77a1dfd6f301"][/audio] [BONUS]

On this bonus episode of "Jen Horonjeff is Noncompliant," Jen brings to Matthew Zachary's attention the idea that patients who enroll in clinical trials should more than benefit from the therapeutic aspects of treatment. After all, aren't they essentially helping a private sector on their go-to-market drug approval and commercialization strategy? After all, if you're helping a business make more money, shouldn't you be entitled to some of that sweet, sweet cheddar yourself? Say, perhaps, some equity stake in their growth? Food for thought because inquiring minds want to know.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kenny Kane

Kenny Kane is an entrepreneur, writer, and nonprofit innovator with 15+ years of experience leading organizations at the intersection of business, technology, and social impact. He is the CEO of Firmspace, CEO of the Testicular Cancer Foundation, and CTO/co-founder of Gryt Health.

A co-founder of Stupid Cancer, Kenny has built national awareness campaigns and scaled teams across nonprofits, health tech, and real estate. As an author, he writes about leadership, resilience, and building mission-driven organizations.

Previous

VAX ON: A New Weekly Roundup of Healthcare News Fuckery
Next

Dr. Mark Lewis Is the Twitter We're Looking For